Photodynamic therapy of cancer: An update†‡
Patrizia Agostinis,Kristian Berg,Keith A. Cengel,Thomas H. Foster,Albert W. Girotti,Sandra O. Gollnick,Stephen M. Hahn,Michael R. Hamblin,Michael R. Hamblin,Asta Juzeniene,David Kessel,Mladen Korbelik,Johan Emelian Moan,Johan Emelian Moan,Pawel Mroz,Dominika Nowis,Jacques Piette,Brian C. Wilson,Jakub Golab,Jakub Golab +19 more
Reads0
Chats0
TLDR
The photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells as discussed by the authors, which can prolong survival in patients with inoperable cancers and significantly improve quality of life.Abstract:
Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments. With a number of recent technological improvements, PDT has the potential to become integrated into the mainstream of cancer treatment. CA Cancer J Clin 2011;61:250-281. V Cread more
Citations
More filters
Journal ArticleDOI
Functional Nanomaterials for Phototherapies of Cancer
Journal ArticleDOI
BODIPY dyes in photodynamic therapy.
TL;DR: The attributes of BODIPY dyes for PDT are summarized, and substituents with appropriate oxidation potentials are summarized in some related areas.
Journal ArticleDOI
The Hippo pathway and human cancer
TL;DR: The evidence for the Hippo pathway as a cancer signalling network is appraised, and potential mechanisms by which Hippo pathways activity is altered in cancer and emerging therapeutic strategies are discussed.
Journal ArticleDOI
New photosensitizers for photodynamic therapy
TL;DR: The dual-specificity of PDT relies on accumulation of the PS in diseased tissue and also on localized light delivery, and future directions include photochemical internalization, genetically encoded protein PSs, theranostics, two-photon absorption PDT, and sonodynamic therapy using ultrasound.
Journal ArticleDOI
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
TL;DR: The current status and possible opportunities for ROS generation for cancer therapy are summarized and it is hoped this review will spur pre-clinical research and clinical practice for ROS-mediated tumour treatments.
References
More filters
Journal ArticleDOI
Photodynamic therapy for cancer
TL;DR: PDT is being tested in the clinic for use in oncology — to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin.
Book
Photodynamic Therapy
TL;DR: A comprehensive review of mechanisms of subcellular and tumor localization of photosensitizing agents, as well as of molecular, cellular, and tumor responses associated with photodynamic therapy, are discussed.
Journal ArticleDOI
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.
Walter Stummer,Uwe Pichlmeier,Thomas Meinel,Otmar D. Wiestler,Friedhelm E. Zanella,Hans-Jürgen Reulen +5 more
TL;DR: Tumour fluorescence derived from 5-aminolevulinic acid enables more complete resections of contrast-enhancing tumour, leading to improved progression-free survival in patients with malignant glioma.
Journal ArticleDOI
Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.
TL;DR: In the ongoing clinical trial of ALA-induced Pp IX photodynamic therapy, the response rate for basal cell carcinomas following a single treatment has been 90% complete response and 7.5% partial response for the first 80 lesions treated.
Journal Article
Photoradiation therapy for the treatment of malignant tumors
Thomas J. Dougherty,Jerome E. Kaufman,Abraham Goldfarb,Kenneth R. Weishaupt,Donn Boyle,Arnold Mittleman +5 more
TL;DR: Deep-seated and pigmented tumors required a higher dose of drug for effective treatment than did the more superficial and nonpigmented lesions, and a high therapeutic ratio between tumor and skin response has been obtained.